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recurrent and disabling chronic sciatica
associated with post-operative peridural
lumbar fibrosis: results of a double-blind,
placebo randomized controlled study
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Introduction: The aim of this study was to assess the efficacy and safety of tumor necrosis factor (TNF)-α inhibition
with infliximab (IFX) in treating recurrent and disabling chronic sciatica pain associated with post-operative
peridural lumbar fibrosis.
Method: A double-blind, placebo-controlled study randomized 35 patients presenting with sciatica pain associated
with post-operative peridural lumbar fibrosis to two groups: IFX (n = 18), a single intravenous injection of 3 mg/kg
IFX; and placebo (n = 17), a single saline serum injection. The primary outcome was a 50 % reduction in sciatica
pain on a visual analog scale (VAS) at day 10. Secondary outcomes were radicular and lumbar VAS pain at day 0
and radicular and lumbar VAS pain, Québec disability score, drug-sparing effect and tolerance at days 10, 30, 90,
and 180.
Results: At day 10, the placebo and IFX groups did not differ in the primary outcome (50 % reduction in sciatica
pain observed in three (17.6 %) versus five (27.8 %) patients; p = 0.69). The number of patients reaching the patient
acceptable symptom state for radicular pain was significantly higher in the placebo than IFX group after injection
(12 (70.6 %) versus five (27.8 %) patients; p = 0.01). The two groups were comparable for all other secondary
outcomes.
Conclusion: Treatment with a single 3 mg/kg IFX injection for post-operative peridural lumbar fibrosis-associated
sciatica pain does not significantly reduce radicular symptoms at day 10 after injection.
Trial registration: ClinicalTrials.gov NCT00385086; registered 4 October 2006 (last updated 15 October 2015).
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The prevalence of persistent or recurrent post-operative
back or lower limb pain in patients who undergo discec-
tomy or laminectomy is up to 15 % [1], and manage-
ment remains challenging. Recurrent symptoms in the
legs are thought to be related to recurrent disc hernia-
tion, persistent herniated fragment, spinal stenosis, or
post-operative peridural fibrosis secondary to scar for-
mation [2, 3]. Extended peridural fibrosis is associated
with poor surgical outcomes in 24 % of patients after
disc herniation surgery [3]. Peridural scarring is consist-
ently observed after spinal surgery including discectomy
[4, 5] or laminectomy [6, 7]. However, with extended
and adhesive post-operative peridural fibrosis being as-
sociated with inflammatory changes at the surgical site,
nerve root and dural sac neuromechanics are impaired,
which ultimately leads to nerve root compression, ab-
normal dura and nerve root bounding and traction dur-
ing back and limb movements [1, 8]. Peridural fibrosis
may also impair the diffusion of nutrients causing nerve
root starvation [9]. Patients with post-operative peridural
lumbar fibrosis-associated sciatica pain often experience
loss of function, disability and impaired quality of life
and can require the use of opioid analgesics [10]. Etio-
logic diagnosis of recurrent or persistent post-operative
sciatica is currently based on magnetic resonance im-
aging (MRI), which helps distinguish central and lateral
spinal stenosis from disc herniation, persistent herniated
fragment or peridural fibrosis [11]. In the case of
peridural fibrosis, MRI demonstrates hyposignals in T1-
weighted sequences with enhancement after gadolinium
injection and hypersignals in T2-weighted sequences of
the fibrotic tissue in the peridural space.
Key and Ford first demonstrated that experimental de-
struction of the intervertebral disc peripheral annulus
fibrosus resulted in peridural scarring [4]. Three factors
causing scar formation were peridural fat destruction,
peridural hematoma and invasion of the surgical trajec-
tory by paravertebral muscle fibers [7]. Treatments tar-
geting one of these three factors included: interposition
of biological material such as fat and animal collagen fi-
bers [12–16]; nonbiological material such as absorbing
gelatin sponge, silastic membrane, wax for bone
hemostasis or polyglactine 910 [7, 13, 15, 17–19]; and
viscous material such as carboxymethylcellulosis or so-
dium hyaluronate [15, 20–22], with only limited efficacy.
Radiotherapy [23, 24] and treatment with human recom-
binant interferon-γ [25] and D-penicillamine [26, 27]
also demonstrated little efficacy. Surgery aiming to re-
move peridural fibrosis was abandoned because of poor
mid- and long-term outcomes, and the high incidence of
adverse events [2, 28–31]. The most frequently used
treatment is intradural [32] or peridural corticosteroid
injections [33]. However, controlled trials addressingtheir efficacy in the setting of sciatica pain associated
with post-operative peridural lumbar fibrosis are lacking.
Only one randomized controlled study compared the ef-
ficacy of forceful peridural corticosteroid injections via
the sacral hiatus to simple peridural corticosteroid injec-
tions on sciatica pain ascribed to post-operative lumbar
spinal fibrosis. At 6-month follow-up, the proportion of
patients with sciatica relief was significantly higher with
forceful than simple injection (29 (45 %) versus 31
(19 %); p = 0.03) [34].
Recently, cytokine inhibitors have generated intense
interest as a possible treatment for radiculopathy. The
inflammatory cytokine tumor necrosis factor (TNF)-α
promotes the production of pro-inflammatory soluble
mediators, angiogenic factors and chemokines by various
cell types and tissues [35]. TNF-α also promotes tissue
fibrosis by stimulating fibroblast proliferation and
modulating their chemotaxis [36]. In addition, TNF-α
blockade with anti-TNF-α monoclonal antibodies has
demonstrated some efficacy in conditions associated
with tissue fibrosis [37]. In murine models of lung fibro-
sis induced by bleomycin or silicium oxide particles, the
TNF-α level was increased in lung tissue. TNF-α
injection induced changes mimicking those observed in
lung fibrosis, such as increased number of fibroblasts,
collagen deposits and necrosis. Conversely, treatment
with TNF-α blockers significantly reduced lung fibrosis
[38, 39]. Consistently, TNF-α played an important role
in a porcine bronchial model of obliterative bronchiolitis
with fibrosis, and its blockade was associated with
decreased lesions [40]. Most recently, topical application
of etanercept, a TNF-α blocker, was effective in reducing
epidural fibrosis in rats after laminectomy [41].
Altogether, clinical and experimental data suggest a
pathogenic role of TNF-α in scar formation and fibrotic
processes. We hypothesized that blocking TNF-α may
be of interest in management of post-operative peridural
lumbar fibrosis, and we aimed to assess the efficacy and
safety of TNF-α inhibition with infliximab (IFX) on the
associated sciatica pain 10 days after the treatment.
Methods
Design
We conducted a parallel-group, double-blind, random-
ized placebo-controlled monocentric study in a tertiary
care hospital (Cochin Hospital, Paris, France).
Patient selection
Patients referred to our rehabilitation department for
recurrent sciatica after discectomy were screened.
Inclusion criteria were age >18 years old, sciatica post-
discectomy, radicular pain measured on a visual analog
scale (VAS) >40 mm and inability to perform usual activ-
ities, surgical discectomy (between 2 years and 6 months
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the discectomy, MRI with gadolinium injection <6 months
and performed >6 months after the discectomy, presence
of peridural fibrosis on MRI, and failure of peridural injec-
tion treatment. Exclusion criteria were untreated chronic
psychiatric disorders, presence of a conflict between the
nerve root and herniated disc or disc fragments or spinal
stenosis, severe cognitive impairment, inability to under-
stand and speak French, enrollment in another clinical
trial in the previous 3 months, and contraindications to
IFX treatment including previous allergic reactions to IFX
or its components, classes III or IV cardiac failure, active
or latent tuberculosis evidenced by clinical examination,
tuberculin intra-dermal reaction and chest X-ray, severe
infections, pregnancy, breastfeeding, absence of contra-
ception for women, and cancer <5 years.
Patient characteristics at baseline
The following parameters were recorded for each patient
at baseline: age; sex; height; weight; retirement and sick
leave status; lumbar, radicular and neuropathic pain on a
VAS (0–100 mm); Québec disability score (20 items;
scored from 0 = no disability to 5 = impossible to do;
final score 0–100); self-reported clinically significant
symptoms of anxiety or depression by the Hospital
Anxiety and Depression Scale (HAD-S; seven items re-
lated to anxiety and seven to depression; each item
scored on a scale from 0 to 3; total score ranging from
0 = no depression, no anxiety to 21 =maximal depres-
sion, maximal anxiety), the Fear-Avoidance Beliefs
Questionnaire score (FAB-Q; five items related to phys-
ical activity and seven to work; each item scored on a
scale from 0 = “do not at all agree” to 6 = “completely
agree”; total score ranging from 0 = low fear-avoidance
beliefs to 24 for the physical activity dimension or 42 for
the work dimension, maximal fear-avoidance beliefs);
number of lumbar surgeries; time between surgery and
recurrent radicular pain; time between surgery and in-
clusion; and co-interventions.
MRI examination
All patients had a lumbar MRI with T1, T2 and T1 with
gadolinium injection sequences. Lumbar MRI findings
were examined independently by a blinded assessor at
baseline for the following parameters: presence or ab-
sence of a retractile scar, nerve root enhancement, nerve
root enlargement, arachnoiditis, and Modic 1 vertebral
endplate subchondral bone changes.
Intervention
The IFX group received a single intravenous infusion of
3 mg/kg IFX (REMICADE, Schering-Plough Centocor,
B.V., AMM n° EU/1/99/116/001; CIP 562 070.1) over a
2-hour period, with vital signs assessed by a physicianfor the first 10 minutes, then by a nurse for the rest of the
infusion time and for an additional 2 hours. The placebo
group received a single saline serum infusion (9 % sodium
chloride, Maco Pharma) over a 2-hour period, with vital
signs assessed by a physician for the first 10 minutes,
then by a nurse for the rest of the infusion time and
for an additional 2 hours. Co-interventions were
allowed and recorded. Unauthorized co-interventions
were immunosuppressants.
Outcome measures
The primary outcome was 50 % reduction in sciatica pain
measured on a VAS (0–100 mm) at day 10. Secondary
outcomes were sciatica pain assessed by a VAS at 2 hours
and days 30, 90 and 180; lumbar pain assessed by a VAS at
2 hour sand days 10, 30, 90 and 180; patient acceptable
symptom state (PASS) defined as a VAS score <40 mm;
and absolute and relative minimum clinically important
improvement (MCII) defined as a reduction in VAS-
assessed pain ≥15 mm or ≥20 %, respectively, at 2 hours
and day 10; Québec disability score; co-interventions; and
tolerance at days 0, 10, 30, 90 and 180.
Tolerance
Adverse effects during infusion or during follow-up,
such as anaphylaxis, fatigue, chest pain, dyspnea, head-
ache, vertigo, dizziness, abdominal pain, nausea, diar-
rhea, dyspepsia, liver test abnormalities, rash, flush,
pruritus, urticaria, skin dryness, increased sweating, re-
spiratory tract infections, sinusitis, and viral infection
were recorded. In the case of a reaction to infusion, infu-
sion speed was reduced.
Sample size
To achieve a 50 % reduction in sciatica VAS pain score
between IFX and placebo groups, with an α risk of 0.05,
a power (1-β) of 0.80, and predicted improvement in
pain scores of 10 % in the placebo group and 60 % in
the IFX group, the number of participants needed was
17 in each group (two-sided chi-square test). With an
estimated 10 % of patients lost to follow-up or present-
ing latent or active tuberculosis, we sought to include 20
patients in each group.
Randomization and allocation concealment
Patients who met the inclusion criteria and agreed to
participate were randomly assigned to the IFX or pla-
cebo group. The randomization process was centralized
at the coordinating office (Unité de Recherche Clinique,
Cochin Hospital), which had no involvement in the enroll-
ment, follow-up, or assessment of participants. A statisti-
cian produced a computer-generated randomization list at
the coordinating office with block size of 4. Once the
screening process was complete, the investigator sent a
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domly assigned the patient to a treatment and faxed the
investigator the allocated treatment. IFX and placebo
doses were prepared by the pharmacy of the hospital
according to the randomization list.Blinding
Patients and assessors were blinded to the treatment
assigned. Presentations, treatment administration and clin-
ical monitoring of the treatments were strictly identical for
each patient. Labeling was anonymized by the pharmacy.Statistical analysis
Data analysis involved the use of SAS 9.3 (SAS Institute,
Cary, NC, USA). Blinded statisticians (MBB, SG and
LQ) performed the statistical analyses at an independent
center (Unité de Biostatistique et d’Épidémiologie, Hôtel
Dieu, GH Cochin). All analyses were performed on an
intent-to-treat basis, in that all patients were considered
in the analysis and were analyzed in the group to which
they had been assigned. Treatment of missing data in-
volved the last-observation-carried-forward method. For
descriptive analyses, qualitative variables are reported
with absolute and relative frequencies, and quantitative
variables with median (interquartile range (IQR)). For
comparative analysis, qualitative variables were com-
pared by chi-square test or Fisher’s exact test in cases of
low frequency of the observed event. Quantitative vari-
ables were compared by Student t test or nonparametric
Wilcoxon Mann-Whitney test if the samples were in-
sufficient. VAS at day 10 was also compared quantita-
tively using an analysis of covariance (ANCOVA) to
control for baseline VAS measure imbalanced between
treatment groups.Fig. 1 Flow of patients in the trial. IFX InfliximabEthics approval
In accordance with L.1123-6 article of the French Health
Code, the study protocol was submitted and approved
by the local ethics committee (Comité consultatif de
Protection des Personnes en Recherche Biomédicale de
l’Île-de-France). All patients gave written informed
consent to participate.
Role of the funding source
The Assistance Publique-Hôpitaux de Paris (Project no.
P050312) funded the study. The funding source was not
involved in the design or conduct of the study or collec-
tion, management, and analysis of the data. It was not
involved in the writing or final approval of the manu-
script. Authors did not receive compensation or funding
for conducting independent data analyses. The corre-
sponding author had full access to all the data in the
study and takes responsibility for the integrity of the
data and the accuracy of the data analysis.
Results
Patient recruitment
In total, 38 patients met the inclusion criteria; two were
excluded because of evidence of tuberculosis during the
screening. From February 2007 to December 2011, we
randomly assigned 18 patients to the placebo group and
18 to the IFX group. One patient was lost to follow-up
in the placebo group (withdrew after randomization and
before treatment) and none in the IFX group. Overall,
data were available for analysis for 17 patients in the
placebo group and 18 in the IFX group (Fig. 1).
Baseline characteristics of patients
The median age was 44.0 years (range 38.0–8.3 years),
and the male:female ratio was 1:1; 31 patients (88.6 %)
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median Québec score was 48.0 (37.0–63.0). Patients
underwent from one to four lumbar surgeries before
inclusion, with a median (IQR) time between surgeryTable 1 Patient demographics, low back pain characteristics, and M
Age (years), median (IQR)
Male sex, n (%)
BMI (kg/m2), median (IQR)
Retired, n (%)
Sick leave, n (%)
Lumbar pain (VAS (0–100 mm)), median (IQR)
Radicular pain, (VAS (0–100 mm)), median (IQR)
Neuropathic pain, n (%)
Neuropathic pain (VAS (0–100 mm)), median (IQR)
Québec score (0–100), median (IQR)
HAD-S, median (IQR)
HAD anxiety score (0–21)
HAD depression score (0–21)
FAB-Q, median (IQR)
FAB-Q work subscale score (0–42)
FAB-Q physical activity subscale score (0–24)
Number of lumbar surgeries, n (%)
1
2
3
4
Time between surgery and recurrent radicular pain (days), median (IQR)
Time between last surgery and inclusion (years), median (IQR)
Co-interventions, n (%)
Analgesics
Grade 1
Grade 2
Grade 3
Nonsteroidal anti-inflammatory drugs
Corticosteroids
Antidepressants
Anxiolytics
Antiepileptics
Retractile scar, n (%)
Nerve root enhancement, n (%)
Nerve root enlargement, n (%)
Arachnoiditis, n (%)
Modic 1 changes, n (%)
BMI Body mass index, FAB-Q Fear Avoidance Beliefs Questionnaire, HAD-S Hospital A
resonance, imaging, N Absolute frequency, VAS Visual analog scaleand recurrent radicular pain of 92.0 (61.0–153.0)
days, and a median (IQR) time between the last
surgery and inclusion of 2.3 (1.6–3.6) years. Co-
interventions included analgesics, nonsteroidal anti-RI features at baseline
IFX group Placebo group All patients
n = 18 n = 17 n = 35
45.0 (38.0–52.0) 43.0 (40.0–48.0) 44.0 (38.0–8.3)
11 (61.1) 7 (41.2) 18 (51.4)
27.9 (24.8–29.8) 25.8 (23.0–29.0) 26.9 (24.4–29.8)
0 (0) 0 (0) 0 (0)
16 (88.9) 15 (88.2) 31 (88.6)
60.0 (41.0–80.0) 50.0 (26.0–60.0) 58.0 (35.0–70.0)
70.0 (65.0–85.0) 55.0 (50.0–70.0) 65.0 (45.0–76.0)
18 (100) 11 (64.7) 29 (82.9)
62.5 (40.0–75.0) 45.0 (41.0–75.0) 50.0 (41.0–70.0)
55.0 (37.0–68.0) 45.0 (31.0–62.0) 48.0 (37.0–63.0)
10.0 (6.0–15.0) 10.0 (8.0–14.0) 10.0 (6.0–14.0)
9.0 (6.0–11.0) 7.0 (5.0–9.0) 7.5 (6.0–11.0)
33.0 (21.0–41.0) 24.0 (19.0–35.0) 30.0 (20.0–39.0)
14.0 (11.0–19.0) 16.0 (10.0–19.0) 14.0 (10.0–20.0)
9 (50.0) 4 (23.5) 13 (37.1)
3 (16.7) 9 (52.9) 12 (34.3)
4 (22.2) 3 (17.7) 7 (20.0)
2 (11.1) 1 (5.9) 3 (8.6)
77.0 (46.0–142.0) 99.0 (91.0–153.0) 92.0 (61.0–153.0)
1.9 (1.4–3.0) 2.7 (1.8–4.5) 2.3 (1.6–3.6)
15 (83.3) 15 (88.2) 30 (85.7)
14 (77.8) 15 (88.2) 29 (82.9)
9 (50.0) 8 (47.1) 17 (48.6)
12 (66.7) 11 (64.7) 23 (65.7)
2 (11.1) 1 (5.9) 3 (8.6)
5 (27.8) 5 (29.4) 10 (28.6)
2 (11.1) 2 (11.8) 4 (11.4)
9 (50.0) 11 (64.7) 20 (57.1)
3 (16.7) 3 (17.6) 6 (17.1)
8 (44.4) 8 (47.1) 16 (45.7)
13 (72.2) 10 (58.8) 23 (65.7)
14 (77.8) 11 (64.7) 25 (71.4)
11 (61.1) 4 (23.5) 15 (42.9)
3 (16.7) 2 (11.8) 5 (14.3)
10 (55.6) 9 (52.9) 19 (54.3)
nxiety Depression Scale, IFX Infliximab, IQR Interquartile range, MRI Magnetic
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anxiolytics and antiepileptics, and were found in 30
patients (85.7 %). The most frequent MRI lumbar fea-
ture was nerve-root enhancement, seen in 25 patients
(71.4 %), followed by presence of a retractile scar in
23 (65.7 %). Modic 1 vertebral endplate subchondral
bone changes detected by MRI were present in 19 pa-
tients (54.3 %) in total.
Primary outcome
The placebo and IFX group did not differ in the primary
outcome: at day 10, three (17.6 %) versus five (27.8 %) pa-
tients showed a 50 % reduction in sciatica pain (p = 0.69;
Table 2).
Secondary outcomes
In the intent-to-treat analysis, between baseline and
10 days, the median (IQR) absolute change in radicu-
lar VAS pain score in the placebo and IFX group was
0.0 (–30.9 to –10.0) and –14.9 (–50.0 to –3.3) mm,
respectively (p = 0.21) and the median absolute change
in lumbar VAS pain score was 16.7 (–16.7 to –34.6)
and –6.0 (–20.0 to –2.9) mm, respectively (Fig. 2).
When adjusting for baseline VAS radicular pain score, the
ANCOVA analysis did not reveal any treatment effect
(data not shown). The two groups did not differ in all
other secondary outcomes, except for number of patients
reaching the PASS for radicular pain (VAS <40 mm),
which was significantly higher for the placebo than IFX
group at day 0 after injection (12 (70.6 %) versus five
(27.8 %); p = 0.01; Table 2). Overall, radicular and lumbar
pain and disability scores remained stable over time in
both groups (Tables 2 and 3). No drug-sparing effectTable 2 Change in radicular pain at days 0 and 10 after injection
Outcomes IFX group
n = 18
Day 0 after injection
Absolute VAS change, median (IQR) −26.8 (–54.8 to –14.3)
50 % reduction in sciatica pain, n (%) 5 (27.8)
PASS <40 mm, n (%) 5 (27.8)
MCII ≥15 mm, n (%) 12 (66.7)
MCII ≥20 %, n (%) 11 (61.1)
Day 10 after injection
Absolute VAS change, median (IQR) −14.9 (–50.0 to 3.3)
50 % reduction in sciatica pain, n (%) 5 (27.8)
PASS <40 mm, n (%) 4 (22.2)
MCII ≥15 mm, n (%) 9 (50.0)
MCII ≥20 %, n (%) 8 (44.4)
*p <0.05 comparing IFX and placebo groups by Wilcoxon Mann-Whitney test for qu
IFX Infliximab, IQR Interquartile range, MCII Minimum Clinically Important Improvem
analog scalewas observed in the IFX group compared to the
placebo group, whatever the co-intervention assessed
(Appendix 1).Safety
Overall, 128 adverse events were reported, 65 in the
placebo group and 63 in the IFX group, but none was
considered serious or related to treatment. The most fre-
quently reported adverse events were increased radicular
pain, infections, gastrointestinal symptoms, joint pain
and respiratory symptoms, and were observed in 51.4 %,
80.0 %, 40.0 %, 34.3 %, and 20.0 % of patients, respect-
ively, with no significant difference between the two
treatment groups (Appendix 2).Discussion
TNF-α could be a key pro-inflammatory and pro-fibrotic
cytokine in the genesis of post-operative peridural fibrosis
and subsequent painful symptoms. In this double-blind,
randomized controlled trial, we assessed the efficacy and
safety of TNF-α blockade with a single intravenous injec-
tion of IFX, 3 mg/kg, in managing sciatica pain due to
post-operative peridural lumbar fibrosis. A single 3-mg/kg
IFX injection had no clinically significant effect on sciatica
pain as compared with placebo at day 10. The number of
patients reaching the PASS for radicular pain was signifi-
cantly higher in the placebo than IFX group at 2 hours
after injection. In addition, ANCOVA revealed that the
changes in radicular VAS pain at days 0 and 10 after injec-
tion were explained by radicular VAS pain at baseline ra-
ther than a treatment effect (estimated coefficient 0.77
(95 % confidence interval 0.25–1.30), p = 0.01, and 0.87Placebo group All patients p-value
n = 17 n = 35
−56.7 (–73.3 to –28.6) −36.0 (–72.3 to –14.3) 0.22
9 (52.9) 14 (40.0) 0.13
12 (70.6) 17 (48.6) 0.01*
13 (76.5) 25 (71.4) 0.52
13 (76.5) 24 (68.6) 0.33
0.0 (–30.9 to 10.0) −9.2 (–38.5 to 9.1) 0.21
3 (17.6) 8 (22.9) 0.69
4 (23.5) 8 (22.9) 0.94
5 (29.4) 14 (40.0) 0.21
5 (29.4) 13 (37.1) 0.36
antitative variables and Fisher’s exact test for qualitative variables
ent, n Absolute frequency, PASS Patient Acceptable Symptom State, VAS Visual
Fig. 2 Changes in a radicular and b lumbar pain scores measured on a visual analog scale over time in patients receiving infliximab and placebo.
Box-and-whisker plots represent results expressed in median and interquartile range
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all, the treatment was well tolerated, and no serious ad-
verse events related to the treatment occurred during the
study period.
Several hypotheses could explain the lack of efficacy of
a potent active treatment in a randomized controlled
trial, including a high placebo effect or spontaneous im-
provement resulting in sustained beneficial effects in alltreatment groups, the design of the study, insufficient
dose and the lack of efficacy of the drug or the import-
ance of imbalance of baseline VAS.
Intravenous injection is commonly associated with a
powerful placebo effect that can persist for months or even
years and limits the ability to detect effects specific to the
treatment [42]. Consistent with previous reports of an early
placebo effect of saline infusion on sciatica pain [43, 44],
Table 3 Radicular and lumbar pain scores and Québec disability score during follow-up
Time points IFX group Placebo group All patients
n = 18 n = 17 n = 35
Radicular pain, VAS score (0–100 mm)
Day 0 70.0 (65.0–85.0)* 55.0 (50.0–70.0) 70.0 (55.0–80.0)
Day 0 post-injection 55.0 (28.0–70.0) 26.0 (15.0–40.0) 40.0 (18.0–60.0)
Day 10 62.5 (40.0–80.0) 50.0 (40.0–63.0) 58.0 (40.0–75.0)
Day 30 70.5 (60.0–80.0) 48.0 (32.0–60.0) 60.0 (40.0–75.0)
Day 90 70.0 (60.0–80.0) 68.0 (50.0–72.0) 68.0 (52.0–78.0)
Day 180 67.5 (45.0–80.0) 65.0 (30.0–73.0) 65.0 (35.0–80.0)
Lumbar pain, VAS score (0–100 mm)
Day 0 60.0 (41.0–80.0) 50.0 (26.0–60.0) 55.0 (35.0–70.0)
Day 0 post-injection 35.0 (0.0–60.0) 27.0 (5.0–42.0) 30.0 (0.0–60.0)
Day 10 62.5 (34.0–70.0) 40.0 (35.0–70.0) 60.0 (34.0–70.0)
Day 30 60.0 (35.0–70.0) 55.0 (30.0–69.0) 60.0 (30.0–70.0)
Day 90 60.0 (30.0–78.0) 55.0 (45.0–60.0) 55.0 (40.0–70.0)
Day 180 60.0 (35.0–70.0) 50.0 (30.0–70.0) 60.0 (32.0–70.0)
Québec disability score (0–100)
Day 0 55.0 (37.0–68.0) 45.0 (31.0–62.0) 51.0 (37.0–65.0)
Day 10 51.5 (39.0–66.0) 48.0 (39.0–55.0) 51.0 (39.0–59.0)
Day 30 57.5 (38.0–67.0) 45.0 (33.0–55.0) 47.0 (34.0–66.0)
Day 90 53.5 (38.0–69.0) 44.5 (36.0–53.5) 46.5 (38.0–64.0)
Day 180 53.5 (37.0–70.0) 44.0 (34.0–51.0) 48.0 (34.0–60.0)
Data are median (interquartile range)
IFX Infliximab, VAS Visual analog scale
*p<0.05 compared to placebo group
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suggested by the early and strong improvement in radicular
and lumbar pain scores as well as a higher rate of patients
reaching the PASS in the placebo than IFX group at 2 hours
after injection. Korhonen et al. assessed the efficacy of IFX
compared to saline in sciatica by disk herniation; approxi-
mately 15 % of the patients in the saline group had an im-
mediate reduction of at least 75 % of sciatica pain at day 0
[43, 44]. In our study, the immediate placebo effect may
have been greater in the saline group than in the IFX group.
However, determinants of this early placebo effect of intra-
venous injections have not been clearly identified yet. At
day 10, we did not observe a high placebo response that
may have skewed the results for our primary outcome: the
median (IQR) absolute change in radicular VAS pain score
for the placebo and IFX group was 0.0 (–30.9 to 10.0) and
–14.9 (–50.0 to 3.3) mm, respectively (p = 0.21). Contrary
to what has been previously reported in acute or subacute
disk herniation-induced sciatica pain [45], we found no sig-
nificant spontaneous improvement over time for leg pain,
back pain or disability, which therefore did not interfere
with the treatment effect. The stability of symptoms over
the 180-day follow-up is most likely explained by the
chronicity of the fibrotic changes with a median (IQR)duration time between last lumbar surgery and inclusion of
2.3 (1.6–3.6) years and by the severity of the condition, with
high levels of disability and failure of previous treatments.
Moreover, fibrotic processes encompass various stages. In
the earliest stages, local inflammation is thought to play an
important role but might not be important later on. There-
fore, there might be a therapeutic window of opportunity
for anti-inflammatory treatment in the fibrotic process.
For the intervention group, IFX may not have been ad-
ministered at the optimal therapeutic dose or the expos-
ure duration to the drug may not have been long
enough. The dosing regimen we used was based on pre-
vious published studies addressing the efficacy of intra-
venous IFX for treatment of acute or subacute disk
herniation-induced sciatica pain [46] designed with a
single injection of 3 mg/kg [47, 48] or 5 mg/kg IFX [43,
44]. This design might not have been appropriate for a
more chronic inflammatory condition such as peridural
fibrosis. Indeed, in chronic inflammatory conditions,
such as rheumatoid arthritis, a dose optimization is rec-
ommended every 8 weeks, starting from 3 mg/kg [49].
However, in the absence of previously published data,
and considering the balance of risks and benefits of
TNF-α blockade, we did not optimize the IFX dose and
Appendix 1
Table 4 Co-interventions during follow-up
Timepoints IFX Group n=18 Placebo group n=17 Total n=35
Analgesics
Day 0 14 (77.8) 15 (88.2) 29 (82.9)
Day 10 14 (77.9) 16 (94.1) 30 (85.7)
Day 30 15 (83.3) 16 (94.1) 31 (88.6)
Day 90 14 (77.8) 16 (94.1) 30 (85.7)
Day 180 15 (83.3) 15 (88.2) 30 (85.7)
Non-steroidal anti-inflammatory drugs
Day 0 5 (27.8) 5 (29.4) 10 (28.6)
Day 10 5 (27.8) 7 (41.2) 12 (34.3)
Day 30 5 (27.8 6 (35.3) 11 (31.4)
Day 90 6 (33.3) 6 (35.3) 12 (34.3)
Day 180 5 (27.8) 5 (29.4) 10 (28.6)
Corticosteroids
Day 0 2 (11.1) 2 (11.8) 4 (11.4)
Day 10 2 (11.1) 2 (11.8) 4 (11.4)
Day 30 2 (11.1) 2 (11.8) 4 (11.4)
Day 90 2 (11.1) 2 (11.8) 4 (11.4)
Day 180 2 (11.1) 2 (11.8) 4 (11.4)
Antidepressants
Day 0 9 (50.0) 11 (64.7) 20 (57.1)
Day 10 11 (61.1) 12 (70.6) 23 (65.7)
Day 30 10 (55.6) 12 (70.6) 22 (62.9)
Day 90 10 (55.6) 12 (70.6) 22 (62.9)
Day 180 9 (50.0) 11 (64.7) 20 (57.1)
Anxiolytics
Day 0 3 (16.7) 3 (17.6) 6 (17.1)
Day 10 3 (16.7) 4 (23.5) 7 (20.0)
Day 30 3 (16.7) 5 (29.4) 8 (22.9)
Day 90 3 (16.7) 4 (23.5) 7 (20.0)
Day 180 3 (16.7) 3 (17.6) 6 (17.1)
Antiepileptics
Day 0 8 (44.4) 8 (47.1) 16 (45.7)
Day 10 10 (55.6) 11 (64.7) 21 (60.0)
Day 30 10 (55.6) 10 (58.8) 20 (57.1)
Day 90 9 (50.0) 9 (52.9) 18 (51.4)
Day 180 8 (44.4) 8 (47.1) 16 (45.7)
Data are absolute frequencies (%).
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despite some experimental and clinical evidence, target-
ing TNF-α in late-stage fibrotic processes might not be
efficient. Only small studies assessed the efficacy of IFX
in fibrosis-associated human diseases including primary
sclerosing cholangitis and pulmonary fibrosis associated
with collagen vascular disease and failed to demonstrate
a clear benefit [50, 51].
In our study, the prevalence of Modic 1 vertebral end-
plate subchondral bone changes was high in both groups
(55.6 % in the IFX group versus 52.9 % in the placebo
group). Modic 1 changes have been reported to be bio-
markers of a subset of nonspecific chronic low back pain
patients who display a particular clinical, biological and
MRI phenotype, leading to the concept of ‘active discopa-
thy’ [52]. The role of local inflammation in the pathogen-
esis of active discopathy has been suggested, with studies
reporting the efficacy of local treatment with intradiscal
anti-inflammatory drugs on lumbar pain [53, 54]. However,
we did not observe any differences between the two groups
on lumbar pain. Hypotheses to explain the lack of efficacy
of anti-TNF-α therapy on lumbar pain are the same as
above. In addition, one can hypothesize that TNF-α might
not be central in generating active discopathy-related
Modic 1 signal and back pain symptoms, as suggested by
animal models [55, 56].
Some factors may limit the generalizability of our
findings. Selecting inclusion and exclusion criteria is chal-
lenging in chronic pain studies. The refractoriness to treat-
ment among patients with a longer duration of symptoms
and significant coexisting psychopathology is likely to result
in lower response rates for treatment participants [57, 58].
However, in our study, clinically significant symptoms of
anxiety and depression assessed by the HAD-S, fear-
avoidance beliefs by the FAB-Q and coping strategies by
the Coping Strategies Questionnaire (data not shown) were
comparable between the two treatment groups over time.
Finally, one of the major challenges of this trial was to en-
roll a sufficient number of patients. One can hypothesize
that the latest improvements in surgical techniques in the
past decade have led to a reduction in the extent of peri-
dural fibrotic scar, and to a decreased prevalence of failed
back surgery syndrome associated with this condition.
Conclusions
This randomized controlled trial did not demonstrate a
clinically significant effect of a single intravenous injec-
tion of IFX at 3 mg/kg. However, from our knowledge of
the pathogenesis of pain, targeting local chronic inflam-
mation and fibrotic processes closely related to painful
symptoms might still be relevant for managing this
condition. We cannot conclude whether a higher dose or
longer or earlier exposure to the drug would have pro-
vided more benefit, and therefore we cannot recommendthe clinical use of TNF-α blockade for recurrent chronic
sciatica pain associated with peridural fibrosis. Further
studies are warranted to confirm our results and to ad-
dress the effects of other anti-inflammatory or anti-
fibrotic agents with dose optimization.
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Adverse events < 10 days ≥ 10 days Total
IFX PBO IFX PBO IFX PBO p-value
Increased neuropathic pain 0 (0) 0 (0) 0 (0) 1 (5.9) 0 (0) 1 (5.9) -
Increased lumbar pain 0 (0) 1 (5.9) 0 (0) 2 (11.8) 0 (0) 4 (23.5) -
Increased radicular pain 5 (27.8) 4 (23.5) 3 (16.7) 2 (11.8) 10 (55.6) 8 (47.1) 0.56
Headache 3 (16.7) 1 (5.9) 2 (11.1) 1 (5.9) 5 (27.8) 2 (11.8) -
Fatigue 2 (11.1) 0 (0) 2 (11.1) 1 (5.9) 5 (27.8) 1 (5.9) -
Hospitalization 0 (0) 0 (0) 0 (0) 2 (11.8) 0 (0) 2 (11.8) -
Hospitalization for lumbo-radicular pain 0 (0) 0 (0) 3 (16.7) 1 (5.9) 3 (16.7) 1 (5.9) -
Infections 4 (22.2) 1 (5.9) 11 (56.0) 13 (76.4) 14 (77.8) 14 (82.4) 0.93
Cardiovascular symptoms 0 (0) 1 (5.9) 0 (0) 1 (5.9) 0 (0) 2 (11.8) -
Skin symptoms 1 (5.6) 1 (5.9) 1 (5.6) 2 (11.8) 2 (11.1) 3 (17.6) -
Gastrointestinal symptoms 2 (11.1) 2 (11.8) 6 (33.3) 4 (23.5) 8 (44.4) 6 (35.3) 0.53
Gynecological symptoms 0 (0) 0 (0) 0 (0) 2 (11.8) 0 (0) 2 (11.8) -
Hormonal manifestations 2 (11.1) 2 (11.8) 0 (0) 0 (0) 2 (11.1) 2 (11.8) -
Joint pain 2 (11.1) 0 (0) 4 (22.2) 6 (35.3) 6 (33.3) 6 (35.3) 0.95
Psychiatric disorder 1 (5.6) 0 (0) 0 (0) 1 (5.9) 1 (5.6) 1 (5.9) -
Respiratory symptoms 0 (0) 1 (5.9) 2 (11.1) 4 (23.5) 2 (11.1) 5 (29.4) -
Sleeping disorder 0 (0) 0 (0) 1 (5.6) 1 (5.9) 1 (5.6) 1 (5.9) -
Sexual disorder 0 (0) 1 (5.9) 1 5.6) 1 (5.9) 1 (5.6) 3 (17.6) -
Traumatism 0 (0) 1 (5.9) 0 (0) 0 (0) 0 (0) 1 (5.9) -
Vertigo 0 (0) 0 (0) 3 (16.7) 0 (0) 3 (16.7) 0 (0) -
Total 22 17 38 44 63 65 -
IFX: IFX group; PBO: placebo group.
Data are absolute frequencies (%).Abbreviations
ANCOVA: Analysis of covariance; FAB-Q: Fear-Avoidance Beliefs
Questionnaire; HAD-S: Hospital Anxiety and Depression Scale; IFX: Infliximab;
IQR: Interquartile range; MCII: minimum clinically important improvement;
MRI: Magnetic resonance imaging; PASS: Patient acceptable symptom state;
TNF: Tumor necrosis factor; VAS: Visual analog scale.
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